Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing partnership to advance CLG-001
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing…
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead
Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead…
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe
Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home Alzheimer’s blood collection
Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home…
Lucid Diligence Brief: Abbott to acquire Exact Sciences
Lucid Diligence Brief: Abbott to acquire Exact Sciences Professional audiences…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: Merck to acquire Cidara Therapeutics
Lucid Diligence Brief: Merck to acquire Cidara Therapeutics Professional…